• A-1155463: Mapping BCL-XL Apoptotic Dependence

  2026-08-23

  BCL-XL inhibitor A-1155463 offers a selective pharmacological probe for dissecting mitochondrial apoptosis and BCL-XL dependence. This article connects its biochemical and in vivo profile with glioblastoma evidence to guide model selection, assay design, and interpretation of resistance phenotypes.

• Cisapride (R 51619): A Translational Cardiac Probe

  2026-08-22

  Cisapride (R 51619) is more than a serotonergic research reagent: its combined 5-HT4 agonism and hERG channel inhibition make it a strategically useful stress test for cardiac electrophysiology research. This article connects molecular pharmacology with iPSC-derived cardiomyocyte phenotyping, deep-learning-enabled screening, and practical assay design.

• Amikacin (BAY416651) in CRE Resistance Research

  2026-08-21

  Carbapenem-resistant Enterobacter cloacae research is moving from isolate detection toward transmission-aware, mechanism-resolved experimentation. This article examines how Amikacin (BAY416651) can serve as a bacterial protein synthesis inhibitor and translational research probe alongside carbapenemase genotyping, plasmid mobility studies, and resistance mechanism analysis.

• ICG001: Mapping β-Catenin in Liver Fibrosis

  2026-08-20

  ICG001 is a selective Wnt/β-catenin pathway inhibitor that helps distinguish β-catenin nuclear localization from CBP-dependent transcription. This article translates new MMP7–E-cadherin findings in biliary atresia into a layer-resolved assay strategy for fibrosis and cancer research.

• Cisapride (R 51619) for Cardiac Assays

  2026-08-20

  Cisapride enables a dual-domain workflow that connects 5-HT4 receptor signaling with hERG-associated cardiac safety questions. This practical guide shows how to combine iPSC-derived cardiomyocytes, high-content imaging, and electrophysiology while controlling solvent, storage, and interpretation risks.

• 3-Aminobenzamide (PARP-IN-1) Assay Guide

  2026-08-19

  A scenario-based guide to using 3-Aminobenzamide (PARP-IN-1), SKU A4161, in cell viability, oxidative-stress, endothelial, and diabetic nephropathy research. It explains concentration selection, solubility, controls, interpretation limits, and practical vendor-selection criteria using product data and peer-reviewed evidence.

• Streptavidin-FITC for Biotin Detection and LNP Tracking

  2026-08-19

  Streptavidin-FITC combines high-affinity biotin recognition with green fluorescence for adaptable imaging, histology, and flow cytometry workflows. Its modular design also supports cargo-specific tracking of lipid nanoparticle trafficking, including experiments that examine how cholesterol alters intracellular delivery.

• EZ Cap™ Firefly Luciferase mRNA Guide

  2026-08-18

  A practical, evidence-based guide to using EZ Cap™ Firefly Luciferase mRNA (SKU R1018) in viability, delivery, translation, and bioluminescence workflows. It addresses reporter interpretation, RNA handling, carrier effects, and vendor selection without overstating what luminescence alone can prove.

• MLN4924 Workflow for Neddylation Research

  2026-08-18

  MLN4924 connects NAE inhibition with practical measurements of CRL activity, substrate turnover, cell-cycle disruption, and apoptosis. This workflow also translates findings from the DCAF13–MeCP2 oocyte study into carefully controlled assays while distinguishing global neddylation effects from pathway-specific biology.

• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-08-17

  This reference study identifies SmD2 acetylation as a regulatory bridge between core spliceosome function, BRCA1/FANC cassette-exon usage, DNA damage, and PARP inhibitor response in hepatocellular carcinoma. Its findings support testing spliceosome and HDAC-related vulnerabilities as a route to DNA repair deficiency targeting, while the reported combination of romidepsin and olaparib remains preclinical.

• S63845 MCL1 Inhibitor: Apoptosis Research Guide

  2026-08-17

  S63845 is a selective MCL1 inhibitor that releases BAX/BAK-dependent mitochondrial apoptosis in MCL1-dependent cancer models. Its biochemical affinity, hematological cancer activity, and practical DMSO workflow make it a useful research tool, but assay-specific sensitivity and preclinical limits require controlled validation.

• EAGLE-1: Oral Gepotidacin for Gonorrhoea

  2026-08-16

  The phase 3 EAGLE-1 trial found that two oral doses of gepotidacin were non-inferior to intramuscular ceftriaxone plus oral azithromycin for microbiological eradication of uncomplicated urogenital gonorrhoea. Its principal contribution is clinical validation of a first-in-class antibacterial mechanism as a potential oral option, although the evidence is limited to a selected urogenital population and does not establish activity at other infection sites.

• β-Elemene Inhibits Adipogenesis via AMPK

  2026-08-15

  The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis and insulin-resistance phenotypes in 3T3-L1 cells, linking reduced lipid accumulation and improved glucose consumption with restoration of AMPK signaling. Its value is primarily mechanistic: the work provides a defined cell-based framework for testing β-Elemene in metabolic research while highlighting the need for pathway-specific validation and in vivo studies.

• Praeruptorin A Translational Research Workflows

  2026-08-14

  Build reproducible Praeruptorin A workflows for ferroptosis, intestinal inflammation, cardiomyopathy research, and cancer-cell invasion studies. This guide connects pathway-level readouts with practical dosing, controls, solvent handling, and troubleshooting decisions.

• Streptavidin-FITC for Smarter Biotin Tracking

  2026-08-14

  A translational perspective on how Streptavidin-FITC converts biotinylated targets into actionable spatial and cellular measurements, with mechanistic insights from recent lipid nanoparticle trafficking research and practical guidance for assay validation.

8513 records 8/568 page Previous Next First page 上5页 678910 下5页 Last page